Guibin Xu

Dr. Guibin Xu

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 January 2024 in Mitochondrion
Verified
Journal Article
Open access
HWHaoran Wang
Haoran Wang
WLWenjun Luo
Wenjun Luo
HCHaoyu Chen
Haoyu Chen
ZCZhiduan Cai
Zhiduan Cai
GXGuibin Xu
Guibin Xu
Mitochondrial dynamics and autophagy play essential roles in normal cellular physiological activities, while abnormal mitochondrial dynamics and mitochondrial autophagy can cause cancer and related disorders. Abnormal mitochondrial dynamics usually occur in parallel with mitochondrial autophagy. Both have been reported to have a synergistic effect and can therefore complement or inhibit each other. Progress has been made in understanding the classical mitochondrial PINK1/Parkin pathway and mitochondrial dynamical abnormalities. Still, the mechanisms and regulatory pathways underlying the interaction between mitophagy and mitochondrial dynamics remain unexplored. Like other existing reviews, we review the molecular structure of proteins involved in mitochondrial dynamics and mitochondrial autophagy, and how their abnormalities can lead to the development of related diseases. We will also review the individual or synergistic effects of abnormal mitochondrial dynamics and mitophagy leading to cellular proliferation, differentiation and invasion. In addition, we explore the mechanisms underlying mitochondrial dynamics and mitochondrial autophagy to contribute to targeted and precise regulation of mitochondrial function. Through the study of abnormal mitochondrial dynamics and mitochondrial autophagy regulation mechanisms, as well as the role of early disease development, effective targets for mitochondrial function regulation can be proposed to enable accurate diagnosis and treatment of the associated disorders.

1 December 2023 in Journal of Endourology
Verified
Journal Article
Closed access
SLSiyang Liang
Siyang Liang
XDXianzhong Duan
Xianzhong Duan
JLJianhe Liu
Jianhe Liu
XZXiongwei Zhang
Xiongwei Zhang
RLRongjie Liang
Rongjie Liang
GXGuibin Xu
Guibin Xu
Introduction: Percutaneous nephrolithotomy (PCNL) is the recommended treatment for 2–4-centimeter renal stones. Minimally-invasive PCNL (MPCNL) with ≤22F sheath was frequently used instead of standard PCNL. MPCNL uses pressurized irrigation to flush out stone fragments through a conventional nephrostomy sheath (cNS), which may result in higher intrarenal pressure (IRP) and longer operating time. The novel vacuum-assisted nephrostomy sheath (vaNS) was developed to mitigate the higher IRP and to facilitate stone removal. It might improve the performance of MPCNL. This prospective and randomized trial compares these two sheaths. Material and Methods: 120 patients with 2-4-centimeter renal stones were accrued in six tertiary medical centers with equal numbers in 2021. 120 patients underwent mPCNL, 60 using 18F cNS and 60 using 18F vaNS, in a prospective and randomized assignment. The primary outcome measurement is decrease in IRP. The secondary outcome is efficacy in stone retrieval. Results: The IRP was lower with vaNS than cNS: mean IRP during the lithotripsy was 12.0±2.7 mmHg with vaNS vs. 20.4±6.0 mmHg with cNS, P=0.000. IRP duration ≥30mmHg was shorter with vaNS than cNS (6.7±7.4 seconds vs. 113.4±222.7 seconds, P=0.001). vaNS has shorter stone removal time (26.9±14.3 vs. 35.7±11.8min., P=0.000). Stone extraction rate was higher (166.4±88.1 vs. 90.4±31.7mm³/min, P=0.000). Stone grasper usage was less (1.4±2.6 vs. 11.9±9.7, P=0.000). vaNS maintained the safety profile. Blood loss, creatinine changes, perioperative complications, and hospital stays were the same in both groups, all P>0.05. Conclusion: MPCNL for stones 2-4cm using vaNS has shorter stone removal time, higher stone extraction rate, and less use of stone extractor. vaNS is superior to cNS at reducing intrarenal pressure and is associated with improved SFRs at 3-day but not at 30-day post-operatively.

22 June 2023 in Urolithiasis
Verified
Journal Article
Closed access
PDF file
DWDong Wang
Dong Wang
YXYuyu Xu
Yuyu Xu
ZLZhen Liu
Zhen Liu
JLJian Liang
Jian Liang
DLDehui Lai
Dehui Lai
GXGuibin Xu
Guibin Xu

28 August 2024 in Materials Science and Engineering: C
Verified
Journal Article
Closed access
SKShahid Ali Khan
Shahid Ali Khan
ZRZia Ur Rahman
Zia Ur Rahman
AJAimen Javed
Aimen Javed
ZAZubair Ahmad
Zubair Ahmad
ZCZhiduan Cai
Zhiduan Cai
GXGuibin Xu
Guibin Xu

13 March 2024 in Cancer Science
Verified
Journal Article
Open access
PDF file
ZCZhiduan Cai
Zhiduan Cai
WLWenjun Luo
Wenjun Luo
HWHaoran Wang
Haoran Wang
RZRui Zhu
Rui Zhu
YYYaoji Yuan
Yaoji Yuan
GXGuibin Xu
Guibin Xu
Dissolving the lipid droplets in tissue section with alcohol during a hematoxylin and eosin (H&E) stain causes the tumor cells to appear like clear soap bubbles under a microscope, which is a key pathological feature of clear cell renal cell carcinoma (ccRCC). Mitochondrial dynamics have been reported to be closely associated with lipid metabolism and tumor development. However, the relationship between mitochondrial dynamics and lipid metabolism reprogramming in ccRCC remains to be further explored. We conducted bioinformatics analysis to identify key genes regulating mitochondrial dynamics differentially expressed between tumor and normal tissues and immunohistochemistry and Western blot to confirm. After the target was identified, we created stable ccRCC cell lines to test the impact of the target gene on mitochondrial morphology, tumorigenesis in culture cells and xenograft models, and profiles of lipid metabolism. It was found that mitofusin 2 (MFN2) was downregulated in ccRCC tissues and associated with poor prognosis in patients with ccRCC. MFN2 suppressed mitochondrial fragmentation, proliferation, migration, and invasion of ccRCC cells and growth of xenograft tumors. Furthermore, MFN2 impacted lipid metabolism and reduced the accumulation of lipid droplets in ccRCC cells. MFN2 suppressed disease progression and improved prognosis for patients with ccRCC possibly by interrupting cellular lipid metabolism and reducing accumulation of lipid droplets.

16 November 2022 in Journal of Materials Science
Verified
Journal Article
Open access
PDF file
ZCZhiduan Cai
Zhiduan Cai
HZHaoquan Zhuang
Haoquan Zhuang
XLXiezhao Li
Xiezhao Li
SLSiyang Liang
Siyang Liang
WLWenjun Luo
Wenjun Luo
GXGuibin Xu
Guibin Xu
The recurrence and metastasis of renal cell carcinoma aresevere challenges in clinical treatment. At present, it is urgent to find a strategy to solve this problem and improve the therapeutic effect. In this study, we designed a programmed release system of anticancer drugs by preparing a nanofiber system with two kinds of diameters and biomaterials (polylactic acid-glycolic acid (PLGA) and silk protein) as drug carriers (paclitaxel), which inspired the occurrence and pathological microenvironment of renal cell carcinoma. The controlled degradation of PLGA nanofibers as a drug carrier achieved the short-term release of paclitaxel, which could rapidly inhibit the spread and metastasis of renal cancer, while the silk protein nanofibers as a drug carrier with slow degradation could provide the long time and continuous release of paclitaxel to prevent the proliferation of renal cancer cells and inhibit recurrence. The synergistic effect of the sustained release system of paclitaxel successfully achieved inhibition of the recurrence and metastasis of renal cell carcinoma and improve the therapeutic effect of renal cell carcinoma. The paclitaxel release profile showed that the PLGA nanofiber drug system provided controlled release of paclitaxel in the first 14 days, while the silk protein nanofiber system provided a relatively stable and long-duration release of paclitaxel (1 month). In vitro experiments showed that the sustained release system of paclitaxel had a lasting inhibitory effect on the proliferation of renal clear cell carcinoma cells. These results indicated that the sustained release system of paclitaxel could be used as a promising drug delivery system with highly efficient implementations to reduce the frequency of systemic administration and inhibit tumor growth and recurrence, which could provide a new strategy for the clinical applications in renal cell carcinoma microenvironment.